Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock - $0.001 par value
Symbol
CTKB on Nasdaq
Shares outstanding
127,940,509
Price per share
$5.45
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
79,957,211
Total reported value
$277,468,446
% of total 13F portfolios
0%
Share change
+485,442
Value change
+$1,803,915
Number of holders
151
Price from insider filings
$5.45
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13% -8.6% $62,325,105 -$7,355,032 16,531,858 -11% BlackRock, Inc. 30 Jun 2025
VANGUARD GROUP INC 6.1% -17% $29,274,570 -$7,000,400 7,765,138 -19% The Vanguard Group 30 Jun 2025
Topline Capital Management, LLC 5.3% $28,140,515 6,780,847 Topline Capital Management, LLC 25 Sep 2025
BROWN CAPITAL MANAGEMENT LLC 3.9% -33% $17,204,316 -$8,695,650 4,958,016 -34% Brown Capital Management, LLC 30 Sep 2025

As of 30 Sep 2025, 151 institutional investors reported holding 79,957,211 shares of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB). This represents 62% of the company’s total 127,940,509 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 16,547,693 -2.9% 0% $57,420,495
Topline Capital Management, LLC 5.4% 6,944,280 +33% 4.1% $24,096,652
VANGUARD GROUP INC 5.4% 6,933,504 -11% 0% $24,059,258
HHLR ADVISORS, LTD. 5.2% 6,657,030 0% 0.56% $23,099,894
BROWN CAPITAL MANAGEMENT LLC 3.9% 4,958,016 -30% 0.71% $17,204,316
STATE STREET CORP 3.2% 4,084,368 -2.1% 0% $14,172,757
MILLENNIUM MANAGEMENT LLC 2.7% 3,418,382 +270% 0.01% $11,861,786
DIMENSIONAL FUND ADVISORS LP 2.5% 3,217,788 -6.9% 0% $11,165,109
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,783,449 +2% 0% $9,660,505
WELLINGTON MANAGEMENT GROUP LLP 2% 2,541,046 0% $8,817,429
ROYCE & ASSOCIATES LP 1.4% 1,763,262 +27% 0.06% $6,118,519
GOLDMAN SACHS GROUP INC 1.4% 1,737,309 +71% 0% $6,028,461
MORGAN STANLEY 1.1% 1,463,141 +27% 0% $5,077,099
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.86% 1,105,021 +21% 0% $3,834,423
AQR CAPITAL MANAGEMENT LLC 0.8% 1,019,890 -18% 0% $3,539,019
NORTHERN TRUST CORP 0.79% 1,013,583 -7.5% 0% $3,517,132
JACOBS LEVY EQUITY MANAGEMENT, INC 0.64% 824,436 -7.2% 0.01% $2,860,793
RENAISSANCE TECHNOLOGIES LLC 0.62% 795,544 -25% 0% $2,760,538
Bank of New York Mellon Corp 0.53% 673,569 -3.8% 0% $2,337,286
PRINCIPAL FINANCIAL GROUP INC 0.49% 623,306 +8.9% 0% $2,162,871
ACADIAN ASSET MANAGEMENT LLC 0.44% 565,573 +80% 0% $1,958,000
UBS Group AG 0.37% 468,689 -26% 0% $1,626,351
PUBLIC SECTOR PENSION INVESTMENT BOARD 0.33% 426,806 +22% 0.01% $1,481,017
Invesco Ltd. 0.3% 389,126 +13% 0% $1,350,267
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.28% 361,290 +150% 0% $1,253,676

Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 18,446,272 $93,149,417 +$2,435,104 $5.05 69
2025 Q3 79,957,211 $277,468,446 +$1,803,915 $3.47 151
2025 Q2 79,443,660 $270,126,999 +$5,595,595 $3.40 156
2025 Q1 77,562,435 $311,007,060 -$4,129,941 $4.01 159
2024 Q4 77,254,066 $501,381,687 +$11,940,410 $6.49 150
2024 Q3 74,960,438 $415,264,475 -$14,594,710 $5.54 134
2024 Q2 76,167,695 $425,021,401 -$33,168,955 $5.58 126
2024 Q1 76,231,609 $511,489,021 +$11,673,469 $6.71 90
2023 Q4 49,461 $451,084 -$231,938 $9.12 1
2023 Q3 77,486,686 $427,726,875 -$4,040,483 $5.52 107
2023 Q2 77,036,054 $657,934,172 +$69,960,899 $8.54 100
2023 Q1 68,501,762 $629,544,777 +$39,222,348 $9.19 99
2022 Q4 64,020,711 $653,663,900 +$18,334,075 $10.21 99
2022 Q3 60,819,487 $895,259,935 +$127,766,852 $14.72 84
2022 Q2 52,867,580 $566,849,461 +$55,375,462 $10.73 80
2022 Q1 47,595,247 $513,251,453 +$121,245,207 $10.78 71
2021 Q4 35,038,930 $571,924,873 +$5,769,727 $16.32 51
2021 Q3 34,351,774 $744,417,532 +$744,417,961 $21.41 52